PRISM Stock IndexesCurrent Value% Change (Daily)% Change (Inception)Most ActiveTop % GainersTop % Losers
Cannabis$79.105.6%-20.9%TLRY 21,727CLVR 12.957%CVSI -4.595%
EV$57.201.6%-42.8%NKLA 13,152NKLA 9.615%TPGY 0%
Gene Therapy$61.301.5%-38.7%BLUE 5,733BLUE 11.564%BNTC -5%
MedDevices$174.30-0.3%74.3%ATRS 5,230VAPO 20%CHFS 0%
MedDiagnostics$88.10-0.7%-11.9%OPK 2,309NDRA 10%OPGN -17.029%
Solar$95.905.7%-4.1%HYSR 7,523SOL 16.703%SIRC -3.813%
Uranium$81.70-0.8%-18.3%UEC 8,842LEU 2.492%URG -3.906%
Vaccines & Cell Therapy$184.901.2%84.9%SRNE 7,297VXRT 11.111%APOP 0%
Web 3.0$28.002.7%-72.0%MARA 17,366DEFTF 15.2%SNII 0%
There could be over half a dozen other potential buyers for the crypto derivatives exchange, the people told Bloomberg, adding that some of the interested… [Read More]

Prism Daily

Vapotherm (VAPO) Skyrockets 52% in Positive Day for PRISM Emerging MedDevices

Vapotherm (VAPO) soared 52% for the day, with no new press releases. The most recent news coming from VAPO is an amendment to their debt agreement on November 22nd. Prior to that, Vapotherm released their Q3 earnings report, where they…

Lightning eMotors (ZEV) Drops 40% As Company Enters into Exchange Agreement with Convertible Noteholders

Lightning eMotors (ZEV) an electric vehicles company fell 40% in a rough day for EV stocks. The drop also comes shortly after the Company announced they are entering into exchange agreements with certain 7.5% convertible noteholders. The Company exchanged 13.3…

Exagen (XGN) Skyrockets 42% After Q3 Earnings Report

Exagen (XGN) , a medical diagnostic company, skyrocketed 42% the day after posting their Q3 earnings report. Exagen reported a quarterly loss of $0.47 per share versus the Zacks Consensus of a loss of $0.76 per share. Exagen also posted…

Feature Story

Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies

John Docherty, President and Head of Research, Lexaria Bioscience

Lexaria Bioscience (Nasdaq): LEXX is investigating the potential therapeutic utility of its proprietary DehydraTECHTM-CBD against dementia and diabetes, two of the world’s biggest public health crises.

The global dementia drug market is projected to reach $32.3 billion by 2030 diabetes and the diabetes drug market is expected to reach $82.92 billion by 2027.

Lexaria recently demonstrated DehydraTECH-CBD exceptional safety and tolerability in a human hypertension study, along with statistically significant lowering of blood pressure over multiple weeks; something that previous studies by others have failed to evidence. Strong connections have been established between hypertension and dementia and diabetes.

The company’s patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream and has demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs and PDE5 inhibitors. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, an important factor in treating dementia.

We spoke to John Docherty, Lexaria’s President and Head of Research, to find out more.


Traders Lens

Upstart Holdings ($UPST)

$UPST has recently broken below where it opened at its IPO back in late 2020 at around $20. It will be interesting to see if it can break back above $20 or continues to drift downwards.

[More Traders Lens]

Prism View

MicroBot Medical: Market Responds to New Patents; Scientific Advisory Board Appointments

Micro-robotic technology company, MicroBot Medical (Nasdaq: MBOT), has received two new patents for its LIBERTY Robotic System, the world’s first fully disposable robotic system for use in endovascular procedures. MicroBot was issued a design patent allowance by the US Patent…

NeuroMetrix, Inc. To Launch First FDA-Approved Medical Device for Fibromyalgia

  Novel medical device and technology company, NeuroMetrix, Inc. (Nasdaq: NURO), will launch the first and only medical device authorized by the FDA to help reduce the symptoms of fibromyalgia. The full commercial launch of the company’s Quell® Fibromyalgia device…

IceCure’s ProSense® System First and Only Medicare Approved Cryoablation Procedure for Breast Cancer

  Cryoablation technology company, IceCure Medical (Nasdaq: ICCM) has received assignment to a Medicare Payment Group for hospital outpatient payment for its ProSense® System. ProSense is a minimally-invasive procedure that destroys early-stage breast cancer tumors by cryoablation (freezing). In October,…

Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies

Lexaria Bioscience (Nasdaq): LEXX is investigating the potential therapeutic utility of its proprietary DehydraTECHTM-CBD against dementia and…

Asensus Surgical Leases SenhanceⓇ Surgical System to 9th German Hospital; First Pediatric Surgery Program

  Medical device company, Asensus Surgical (NYSE American: ASXC) has announced the first-ever Senhance pediatric surgery…

Verde Bio: Well Count Continues to Rise; New Drilling Begins on Company Properties

Oil and gas company, Verde Bio (OTCQB: VBHI) has announced that with the sustained high oil…

Bionik Laboratories Q2 Fiscal Year 2023 Earnings: New Strategic Direction Increases Outlook for Growth; Revenue Increase of 113% YoY

  Robotics company, Bionik Laboratories Corp. (BNKL) has announced its earnings for the second quarter of…